HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook
HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook Hims & Hers shares tumbled in premarket trading in New York, the most in three months, after the company posted a first-quarter loss and revenue that missed analyst estimates tracked by Bloomberg, as costs rose amid a massive pivot from selling copycat GLP-1 drugs toward branded obesity drugs from Novo Nordisk and Eli Lilly. Revenue for the first quarter came in at $608 million versus the $617.5 million Bloomberg Conse...
Original Source
Read the full article at Zerohedge →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.